The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer

Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete patholo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicine and life 2019-10, Vol.12 (4), p.329-331
Main Authors: Pop, Lucian, Suciu, Ioan Dumitru, Ionescu, Olivia, Ionescu, Paris, Toader, Oana Daniela
Format: Article
Language:English
Subjects:
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer therapies
Cardiac function
Chemotherapy
Clinical trials
Disease-Free Survival
ErbB-2 protein
Female
Humans
Lymph Nodes - pathology
Neoadjuvant Therapy
Neoplasm Staging
Neutropenia
Receptor, ErbB-2 - metabolism
Response rates
Review
Tumors
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete pathologic response in the breast and in the axilla. The purpose of this review is to outline the efficacy of the dual blockade with Trastuzumab and Pertuzumab in the neoadjuvant treatment of high-risk Her-2 positive breast cancer. Electronic databases (Pubmed, Medline, and Cochrane Database of Systematic Reviews) were searched for English- and German-language studies, which were published in the last ten years. The search has been focused on neoadjuvant clinical trials as well as on the data presented in the abstracts published at the San Antonio Breast Cancer Symposium as well as at the annual meeting of the American Society of Clinical Oncology. The results reported in the published clinical trials demonstrated a higher pathologic complete response rate in breast and lymph nodes after using targeted therapy with two anti-Her-2/neu agents - Trastuzumab and Pertuzumab in combination with neoadjuvant chemotherapy for early-stage Her-2/neu positive breast cancers. The pathologic complete response rate is the most important prognostic marker in Her-2/neu positive tumors, a higher pathologic complete response rate being demonstrated to be associated with a better survival outcome in terms of higher overall survival and disease-free survival rates.
ISSN:1844-122X
1844-3117
DOI:10.25122/jml-2019-0115